ADMA Biologics and some executives face a securities fraud lawsuit alleging they misled investors by inflating revenue through excess shipments of their product ASCENIV and hiding a related-party distribution deal. The truth surfaced after a report in March 2026 revealed unsold inventory was driving reported growth, causing the stock price to drop sharply. Investors who bought ADMA stock between August 2024 and March 2026 and suffered losses may be eligible to join the lawsuit. The deadline to seek lead plaintiff status is August 10, 2026, and investors are encouraged to contact Block & Leviton for more information or to participate.
A class action lawsuit has been filed against ADMA Biologics, alleging the company failed to disclose an undisclosed related party transaction, engaged in channel stuffing to inflate revenue, and lacked proper internal controls. The lawsuit covers se...
A shareholder class action lawsuit has been filed against ADMA Biologics, alleging the company made false and misleading statements and failed to disclose key adverse facts. The claims include undisclosed related party transactions, channel stuffing ...
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for allegedly inflating its 2025 revenue growth through channel stuffing, a practice where excess product is pushed to distributors to boost sales figures artificially. Culper Resear...
